Literature DB >> 29705397

Autocrine CCL5 promotes tumor progression in esophageal squamous cell carcinoma in vitro.

Yi-Cheng Wu1, Yung-Chi Shen2, John Wen-Cheng Chang3, Jia-Juan Hsieh3, Yen Chu4, Cheng-Hsu Wang5.   

Abstract

The pro-tumoral effects of CCL5 have been identified in numerous cancer types. We successfully cultivated 4 esophageal squamous cell carcinoma (ESCC) cell lines, including TWES-1, TWES-3 and a pair of cell lines derived from primary lesion (TWES-4PT) and metastatic lymph node (TWES-4LN) of the same patient. Whole genome screening showed that TWES-4LN expressed higher levels of CCL5 compared to that of TWES-4PT; quantification of protein secretion displayed comparable results, suggesting that CCL5 could be associated with lymph node metastasis in ESCC. CCL5 knockdown by siRNA significantly reduced basal growth rate, tumor migration and invasiveness in the paired cell lines; whereas this treatment induced cell apoptosis in TWES-1 and TWES-3. CCR5 antagonist maraviroc significantly inhibited tumor migration and invasion in the paired cell lines without affecting tumor growth. Collectively, these results suggest that CCL5 autocrine loop may promote ESCC progression; targeting the CCL5/CCR5 axis could be a potential therapeutic strategy for this deadly disease.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CCL5; Esophageal squamous cell carcinoma; Maraviroc; Tumor progression

Mesh:

Substances:

Year:  2018        PMID: 29705397     DOI: 10.1016/j.cyto.2018.04.027

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  9 in total

Review 1.  Recent Advances Targeting CCR5 for Cancer and Its Role in Immuno-Oncology.

Authors:  Xuanmao Jiao; Omar Nawab; Tejal Patel; Andrew V Kossenkov; Niels Halama; Dirk Jaeger; Richard G Pestell
Journal:  Cancer Res       Date:  2019-07-10       Impact factor: 12.701

Review 2.  The G protein coupled receptor CCR5 in cancer.

Authors:  Chandan Upadhyaya; Xuanmao Jiao; Anthony Ashton; Kishan Patel; Andrew V Kossenkov; Richard G Pestell
Journal:  Adv Cancer Res       Date:  2020-01-10       Impact factor: 6.242

Review 3.  An Update on Glioblastoma Biology, Genetics, and Current Therapies: Novel Inhibitors of the G Protein-Coupled Receptor CCR5.

Authors:  Tamara Lah Turnšek; Xuanmao Jiao; Metka Novak; Sriharsha Jammula; Gina Cicero; Anthony W Ashton; David Joyce; Richard G Pestell
Journal:  Int J Mol Sci       Date:  2021-04-24       Impact factor: 5.923

Review 4.  CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of Receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 Ligands.

Authors:  Jan Korbecki; Szymon Grochans; Izabela Gutowska; Katarzyna Barczak; Irena Baranowska-Bosiacka
Journal:  Int J Mol Sci       Date:  2020-10-15       Impact factor: 5.923

5.  CCL3-CCR5 axis contributes to progression of esophageal squamous cell carcinoma by promoting cell migration and invasion via Akt and ERK pathways.

Authors:  Takayuki Kodama; Yu-Ichiro Koma; Noriaki Arai; Aya Kido; Naoki Urakawa; Mari Nishio; Manabu Shigeoka; Hiroshi Yokozaki
Journal:  Lab Invest       Date:  2020-05-26       Impact factor: 5.662

Review 6.  Cytokine-chemokine network driven metastasis in esophageal cancer; promising avenue for targeted therapy.

Authors:  Ajaz A Bhat; Sabah Nisar; Selma Maacha; Tatiana Correa Carneiro-Lobo; Sabah Akhtar; Kodappully Sivaraman Siveen; Nissar A Wani; Arshi Rizwan; Puneet Bagga; Mayank Singh; Ravinder Reddy; Shahab Uddin; Jean-Charles Grivel; Gyan Chand; Michael P Frenneaux; Mushtaq A Siddiqi; Davide Bedognetti; Wael El-Rifai; Muzafar A Macha; Mohammad Haris
Journal:  Mol Cancer       Date:  2021-01-04       Impact factor: 27.401

7.  Tumor-associated macrophage polarization promotes the progression of esophageal carcinoma.

Authors:  Xin Yuan; Ya Li; An Zhi Zhang; Chen Hao Jiang; Fan Ping Li; Yu Fang Xie; Jiang Fen Li; Wei Hua Liang; Hai Jun Zhang; Chun Xia Liu; Li Juan Pang; Xi Hua Shen; Feng Li; Jian Ming Hu
Journal:  Aging (Albany NY)       Date:  2020-12-15       Impact factor: 5.682

Review 8.  CCL5/CCR5 axis in human diseases and related treatments.

Authors:  Zhen Zeng; Tianxia Lan; Yuquan Wei; Xiawei Wei
Journal:  Genes Dis       Date:  2021-08-26

9.  The effect of CCL5 on the immune cells infiltration and the prognosis of patients with kidney renal clear cell carcinoma.

Authors:  Shuheng Bai; YinYing Wu; Yanli Yan; Haojing Kang; Jiangzhou Zhang; Wen Ma; Ying Gao; Beina Hui; Rong Li; Xiaozhi Zhang; Juan Ren
Journal:  Int J Med Sci       Date:  2020-10-18       Impact factor: 3.738

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.